Simplify Logo
Zeiss

Zeiss

Supplies lithography optics for semiconductor manufacturing

Account Manager - Microsurgical

Full-Time
$70k - $80k/yr

+ Commission + Bonus

Mid
Bachelor's
Manitoba, Canada+1 more

More locations: Vancouver, BC, Canada

Remote

Remote in Canada; no relocation assistance specified.

About the job

Requirements
  • Bachelor’s degree in Business, Marketing, Healthcare Administration, or a related field, or an equivalent combination of education and relevant industry experience.
  • Minimum three (3) years of experience in Strategic Account Management, Key Account Management, or a similar commercial sales role.
  • Proven ability to build and maintain relationships with senior executives and key stakeholders, influencing decision-making and driving business results.
  • Strong consultative selling, strategic account planning, and customer relationship management skills.
  • Demonstrated experience negotiating, developing, and managing commercial agreements and contracts.
  • Excellent presentation skills, including the ability to deliver impactful executive-level and strategic account presentations.
  • Resourceful and solutions-oriented, with the ability to prioritize competing demands and identify opportunities to drive growth.
  • Strong organizational, communication, and interpersonal skills, with the ability to collaborate effectively across cross-functional teams.
  • Self-motivated and capable of working independently in a fast-paced, results-driven environment.
Responsibilities
  • Attain or exceed yearly revenue and profit quotas for region of responsibility.
  • Monitoring & reporting on sales activity, market & competitor's situation
  • Scheduled personalized sales demonstrations to Customers in the Fields of Business of Visualization, Surgical Ophthalmology and Surgical Oncology market in region of responsibility. Customers include but are not to Surgeons (Ophthalmology, Neuro, ENT, P+R, Spine, Gyn, Dental, General) and Oncologists as well as all training on applications and in servicing relevant hospital and clinic staff.
  • Educate and follow up the Surgeons and staff members on the operation, utilization and applications of our product to ensure overall customer satisfaction.
  • Establish/ maintain good relationships with customers and accounts.
  • Develop and implement creative and profitable marketing approaches to the individual demands of the representative’s region.
  • Be responsible and assist in market introductions and launches of new products planning
  • Maintain, analyze and utilize territory records and other information to efficiently organize, plan, execute and measure results. Including SOM, CRM, AR and DSO.
  • Provide timely, accurate, and constructive written and oral communications to management regarding expected sales planned monthly activity.
  • Develop and implement synergy opportunities among other Zeiss team members, companies, Carl Zeiss field service and other corporate partners when such programs arise.
  • All paperwork and other requested information should be furnished in a complete and timely manner.
  • Assist / advise the local sales administration personnel when necessary, on all matters pertaining to processing customer orders, deliveries, etc.
  • Review pending service jobs together with the Service team and offer any assistance that may be required in their execution
  • The position requires the ability to continuously adapt to change and to represent the company as per the strategy implemented by the management, including participation in training sessions and keeping updated on technology changes.
  • A good working relationship with colleagues, service and office personnel is vital.
  • Maintain currency of and adhere to applicable Company and ISO 9001 processes and procedures.
  • Abide by provincial and federal employment laws.
  • Prioritizes inquires and requests while troubleshooting conflicts; ensures adequate focus-time towards company objectives.
Desired Qualifications
  • Two (2) or more years of experience selling surgical capital equipment within the Operating Room environment is considered an asset.

About the company

Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS SMT opened its Korea Innovation Center in July 2026, deepening customer access.
  • July 24, 2026 capacity expansion adds 25,000 square meters in Oberkochen.
  • ASML expects 2027 EUV output growth, with Zeiss optics capacity already expanding.

What critics are saying

  • ASML bought €4.41 billion from Zeiss in 2025; customer concentration is extreme.
  • A prolonged Oberkochen outage would halt ASML production within months.
  • Monument Peak sued Zeiss on February 6, 2026 over Kodak patents.

What makes Zeiss unique

  • ZEISS SMT remains ASML's sole EUV optics supplier in 2026.
  • Oberkochen and Wetzlar are the only places building ASML optical columns.
  • High-NA EUV optics from ZEISS anchor sub-2nm lithography for Intel and TSMC.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.